Alternative Medications for Brinsupri (Brensocatib) in Non-Cystic Fibrosis Bronchiectasis
For patients unable to take brensocatib, the primary alternatives are long-term macrolide antibiotics (azithromycin or erythromycin) or inhaled antibiotics, with the specific choice depending on whether the patient has chronic Pseudomonas aeruginosa infection.
Treatment Algorithm Based on Pathogen Status
For Patients WITH Chronic P. aeruginosa Infection:
First-line alternative: Inhaled colistin 1 MU twice daily delivered through I-neb 1
- This is the preferred inhaled antibiotic with Grade B recommendation
- Extends time to exacerbation and improves quality of life
Second-line alternative: Inhaled gentamicin 1
- Consider if colistin is not tolerated
- Increases time to exacerbation and reduces exacerbation rate
- Important safety precautions:
- Avoid if creatinine clearance <30 mL/min
- Use caution with significant hearing loss or balance issues
- Avoid concomitant nephrotoxic medications
Third-line alternative: Azithromycin or erythromycin 1, 2
- Use if patient cannot tolerate inhaled antibiotics
- Can also be added to inhaled antibiotics for high exacerbation frequency
- Azithromycin dosing: Start with 250 mg three times weekly, increase based on response 1
- Erythromycin: 400 mg twice daily 2
For Patients WITHOUT P. aeruginosa Infection:
First-line alternative: Long-term macrolides 1, 2
- Azithromycin or erythromycin
- Reduce exacerbation number with Grade 1++ evidence
- Critical safety requirements before starting:
- Ensure at least one negative respiratory NTM (non-tuberculous mycobacterial) culture
- Use caution with significant hearing loss or balance issues
Second-line alternative: Long-term oral targeted antibiotic based on sputum culture 1
- Only if macrolides contraindicated, not tolerated, or ineffective
- Must be guided by antibiotic susceptibility testing
Third-line alternative: Long-term inhaled antibiotic 1
- Consider if oral antibiotics are contraindicated, not tolerated, or ineffective
Critical Implementation Points
Patient Selection Criteria:
All alternatives should be considered for patients with ≥3 exacerbations per year despite optimized management 1, 3. The 2026 American College of Chest Physicians guideline specifically recommends long-term macrolides and brensocatib with conditional recommendation and moderate certainty evidence 3.
Before Starting Any Long-Term Antibiotic:
- Review culture and mycobacterial status
- Optimize airway clearance techniques
- Treat other associated conditions
- Ensure respiratory specialist involvement 1
Monitoring Requirements:
- Review patients every 6 months for efficacy, toxicity, and continuing need 1
- Monitor sputum culture and sensitivity regularly (though in vitro resistance may not affect clinical efficacy)
- For macrolides: Regular NTM surveillance
- For inhaled aminoglycosides: Renal function and audiometry
Comparative Efficacy Context
Recent network meta-analysis data shows that among antiinflammatory therapies, macrolides demonstrate the greatest reduction in exacerbation frequency (rate ratio 0.44,95% CI 0.35-0.56), while DPP-1 inhibitors like brensocatib show rate ratio 0.73 (95% CI 0.60-0.88) 4. Notably, DPP-1 inhibitors remain effective even in patients already on long-term macrolides, suggesting these mechanisms can be complementary 4.
Common Pitfalls to Avoid
- Do NOT use inhaled aztreonam - it has higher adverse events and no clinically significant benefit 1
- Do NOT routinely use non-macrolide oral antibiotics without clear evidence of specific pathogen and macrolide contraindication 5
- Do NOT use PDE4 inhibitors, methylxanthines, leukotriene receptor antagonists, CXCR2 antagonists, neutrophil elastase inhibitors, or statins for bronchiectasis treatment 1
- Perform bronchodilator challenge test before starting inhaled antibiotics to assess tolerance 1
Escalation Strategy
If patients continue to have ≥3 exacerbations per year despite Step 3 treatment, consider combining long-term macrolide with long-term inhaled antibiotic 1. For patients with ≥5 exacerbations per year despite maximal therapy, consider regular intravenous antibiotics every 2-3 months 1.